Ayhan Küp1, Cüneyt Toprak2, Emrah Bayam3, Servet İzcı1, Abdulkadir Uslu1, Mehmet Çelık1, İsmail Balaban1, Sinan Cerşıt1, Süleyman Barutçu4, Pınar Demir Gündoğmuş5. 1. University of Medical Sciences Kartal Kosuyolu High Specialty Education and Research Hospital. 2. University of Medical Sciences Sancaktepe Şehit Prof. Dr. İlhan Varank Education and Research Hospital. 3. University of Medical Sciences Ümraniye Education and Research Hospital. 4. University of Medical Sciences Van Education and Research Hospital. 5. University of Medical Sciences Sultan Abdulhamid Han Training and Research Hospital.
Abstract
BACKGROUND: Endothelial cell-specific molecule 1 (ESM-1 or endocan) is an immunoinflammatory marker strongly associated with inflammation, vascular endothelial dysfunction and atherosclerosis. We explored the relationship between serum endocan concentrations and coronary in-stent restenosis (ISR). METHODS: Fifty consecutive patients with ISR and 50 control subjects were included in this study. Clinical data and angiographic characteristics were collected. Serum endocan concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: All included patients were divided into four quartiles based on their concentrations of endocan: quartile 1 (0.62-1.31 ng/mL), quartile 2 (1.33-1.74 ng/mL), quartile 3 (1.75-2.77 ng/mL) and quartile 4 (2.78-4.24 ng/mL). The rates of ISR were 16%, 24%, 68%, and 92%, respectively. The patients in quartile 4 had significantly higher rates of ISR than the other groups (p < 0.001). Logistic regression analysis indicated that endocan concentration [odds ratio = 8.65, 95% confidence interval 3.56-20.94; p < 0.001] was an independent predictor of ISR. Receiver operating characteristic curve analysis was used to explore the relationship between endocan and ISR. Using a cutoff value of 1.625 ng/mL, endocan predicted ISR with a sensitivity of 86% and a specificity of 78%. CONCLUSIONS: Our findings suggest that plasma endocan levels may be a novel biomarker of endothelial dysfunction in patients with ISR.
BACKGROUND: Endothelial cell-specific molecule 1 (ESM-1 or endocan) is an immunoinflammatory marker strongly associated with inflammation, vascular endothelial dysfunction and atherosclerosis. We explored the relationship between serum endocan concentrations and coronary in-stent restenosis (ISR). METHODS: Fifty consecutive patients with ISR and 50 control subjects were included in this study. Clinical data and angiographic characteristics were collected. Serum endocan concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: All included patients were divided into four quartiles based on their concentrations of endocan: quartile 1 (0.62-1.31 ng/mL), quartile 2 (1.33-1.74 ng/mL), quartile 3 (1.75-2.77 ng/mL) and quartile 4 (2.78-4.24 ng/mL). The rates of ISR were 16%, 24%, 68%, and 92%, respectively. The patients in quartile 4 had significantly higher rates of ISR than the other groups (p < 0.001). Logistic regression analysis indicated that endocan concentration [odds ratio = 8.65, 95% confidence interval 3.56-20.94; p < 0.001] was an independent predictor of ISR. Receiver operating characteristic curve analysis was used to explore the relationship between endocan and ISR. Using a cutoff value of 1.625 ng/mL, endocan predicted ISR with a sensitivity of 86% and a specificity of 78%. CONCLUSIONS: Our findings suggest that plasma endocan levels may be a novel biomarker of endothelial dysfunction in patients with ISR.
Authors: Mahmut I Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Yasemin G Kurt; Hilmi U Unal; Tayfun Eyileten; Mahmut Gok; Hakki Cetinkaya; Yusuf Oguz; Sebahattin Sari; Abdulgaffar Vural; Irina Mititiuc; Adrian Covic; Mehmet Kanbay Journal: Kidney Int Date: 2014-07-02 Impact factor: 10.612
Authors: A Lafont; E Durand; J L Samuel; B Besse; F Addad; B I Lévy; M Desnos; C Guérot; C M Boulanger Journal: Circulation Date: 1999-09-07 Impact factor: 29.690